

Lupin announces skin ointment launch in the US

09 October 2018 | News

It is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.



Pharma major Lupin has announced the launch of Clobetasol Propionate Ointment USP 0.05%, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Clobetasol Propionate Ointment USP, 0.05% is the generic equivalent of Fougera Pharmaceuticals Inc.'s Temovate Ointment, 0.05%. It is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Clobetasol Propionate Ointment USP 0.05% had annual sales of approximately \$ 93.4 million in the US.